1. Rutgeerts P, Vermeire S, Van AG. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007; 56(4): 453–455.
2. Caspersen S, Elkjaer M, Riis L et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008; 6(11): 1212–1217.
3. Colombel JF, Loftus EV Jr., Tremaine WJ et al. The safety profile of infliximab in patients with Crohn‘s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126(1): 19–31.
4. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58(4): 501–508.
5. Peyrin-Biroulet L, Deltenre P, Branche J et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn‘s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6(6): 644–653.
6. Rahier JF, Buche S, Peyrin-Biroulet L et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010; 8(12): 1048–1055.
7. Fiorino G, Allez M, Malesci A et al. Review article: antiTNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29(9): 921–927.
8. Van Moerkercke W, Ackaert C, Jurgens M et al. Anti-TNFa Induced Severe Arthralgia as a manifestation of Autoimmunity? Gastroenterology 2010; 138(5): S60–S61.
9. Lugering A, Schmidt M, Lugering N et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn‘s disease by using a caspase-dependent pathway. Gastroenterology 2001; 121(5): 1145–1157.
10. Shen C, Assche GV, Colpaert S et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21(3): 251–258.
11. Lugering A, Lebiedz P, Koch S et al. Apoptosis as a therapeutic tool in IBD? Ann N Y Acad Sci 2006; 1072: 62–77.
12. Enari M, Sakahira H, Yokoyama H et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391(6662): 43–50.
13. Napirei M, Ricken A, Eulitz D et al. Expression pattern of the deoxyribonuclease 1 gene: lessons from the Dnase1 knockout mouse. Biochem J 2004; 380 (Pt 3): 929–937.
14. Zhang J, Xu M. Apoptotic DNA fragmentation and tissue homeostasis. Trends Cell Biol 2002; 12(2): 84–89.
15. Ueki M, Takeshita H, Fujihara J et al. Caucasian-specific allele in non-synonymous single nucleotide polymorphisms of the gene encoding deoxyribonuclease I-like 3, potentially relevant to autoimmunity, produces an inactive enzyme. Clin Chim Acta 2009; 407(1–2): 20–24.
16. Martinez-Valle F, Balada E, Ordi-Ros J et al. DNase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features. Lupus 2009; 18(5): 418–423.
17. Martinez VF, Balada E, Ordi-Ros J et al. DNase 1 and systemic lupus erythematosus. Autoimmun Rev 2008; 7(5): 359–363.
18. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 170: 2–6.
19. Stange EF, Travis SP, Vermeire S et al. European evidence based consensus on the diagnosis and management of Crohn‘s disease: definitions and diagnosis. Gut 2006; 55 (Suppl 1): 1–15.
20. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42(1): 121–130.
21. Harrison MJ, Dixon WG, Watson KD et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti--tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68(2): 209–215.
22. Lee HH, Song IH, Friedrich M et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 200; 156(3): 486–491.
23. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum 2008; 37(4): 251–255.
24. Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 2003; 15(4): 380–386.
25. Vermeire S, Noman M, Van AG et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn‘s disease: a prospective cohort study. Gastroenterology 2003; 125(1): 32–39.
26. Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15(17): 2067–2073.
27. Walport MJ. Lupus. DNase and defective disposal of cellular debris. Nat Genet 2000; 25(2): 135–136.
28. Kim I, Hur NW, Shin HD et al. Associations of DNase IV polymorphisms with autoantibodies in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2008; 47(7): 996–999.
29. Belguith-Maalej S, Hadj-Kacem H, Kaddour N et al. DNase1 exon2 analysis in Tunisian patients with rheumatoid arthritis, systemic lupus erythematosus and Sjogren syndrome and healthy subjects. Rheumatol Int 2009; 30(1): 69–74.
30. Dittmar M, Bischofs C, Matheis N et al. A novel mutation in the DNASE1 gene is related with protein instability and decreased enzyme activity in thyroid autoimmunity. J Autoimmun 2009; 32(1): 7–13.
31. D‘Auria F, Rovere-Querini P, Giazzon M et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med 2004; 255(3): 409–418.
32. Bourne T, Fossati G, Nesbitt A. A PEGylated Fab‘ fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 2008; 22(5): 331–337.